Fulcrum Therapeutics (FULC)

• Market cap: $642M
• 1 day: 1.88%
• 5 days: -9.49%
• 1 month: -2.6%
• 3 months: 27.19%
• 6 months: 40.2%
• Year to date: -10.9%
• 1 year: 154.05%
• 5 years: -22.78%
• 10 years: -27.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Employees: 45